For full functionality of this website it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser

Session Details

Protecting Your Brand in a New Market: How to Build a Global IP Strategy?
Friday, May 31, 2024 08:00 AM - 09:00 AM  
Room 205-207
Roundtable
Organized by: ISCT APAC Industry Committee & ISCT Committee on the Ethics of Cell & Gene Therapy (ECGT)

Moderators
  • Tania Bubela, BSc (Hons), PhD, JD, FCAHS, FRSC, Simon Fraser University, Canada
  • William (Bill) Milligan, BSc, Steminent Biotherapeutics, Inc., Canada
Panelists
  • Megan Levings, PhD, The University of British Columbia, Canada
  • April Wurster, MS, JD, Snell & Wilmer, United States
  • Martin Ostrowski, BS, MS, JD, Kenai Therapeutics (formerly Ryne Biotechnology), United States

Develop an IP and commercialization strategy that promotes product exclusivity across multiple markets without preventing access for patients in healthcare systems with fewer resources

Key Learning Objectives
1. Understand important differences you should be aware of in creating IP strategy for CGT technologies / products vs. small molecule products and other biologics.
2. Discuss key considerations that CGT product developers / enablers should be aware of in creating their international IP Strategy.
3. Explore IP strategy for optimizing your products' value with respect to; manufacturing, applications, markets to protect for global access/equity, to optimize partnering and commercialization potential. 

Megan Levings
Professor
University of British Columbia
Panelist


Bill Milligan
SVP CD & BD
Steminent Biotherapeutics Inc.
Panelist


Martin Ostrowski
General Counsel
Kenai Therapeutics
Panelist


April Wurster
Intellectual Property Partner
Snell and Wilmer
Panelist